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A 36 year old woman with relapsing remitting MS presented with right 
sided spasms, focal seizures and neuropsychiatric symptoms 10 months 
after her first course of alemtuzumab. MRI brain imaging revealed multiple 
foci of T2 hyperintensity. Subsequent blood and CSF testing for PML, 
vasculitis and infective causes was negative. A brain biopsy was performed, 
revealing a prominent perivascular inflammatory infiltrate with multiple 
immune cells including eosinophils, suggesting eosinophilic vasculitis. The 
patient was treated successfully with cyclophosphamide. The potential 
sequelae of alemtuzumab treatment are discussed; this treatable 
complication should be considered when tests for JC virus are negative. 
 
 
Background to case 
  
A 36 year-old female presented in 2005 with right arm clumsiness, and was 
diagnosed with relapsing remitting multiple sclerosis after imaging and CSF 
analysis (fig 1A). Three relapses occurred over the next five years, including 
optic neuritis and right-sided weakness, which responded well to steroids. 
Surveillance MRI in 2011 revealed new lesions, and glatiramer acetate was 
commenced in 2012. Due to adverse effects treatment was stopped, but after 
further relapses dimethyl fumarate was commenced in July 2014. In December 
2014 she experienced another relapse; MRI demonstrated new cervical lesions. 
After MDT discussion, treatment was escalated to alemtuzumab, and she 
received the first 5-day course in March 2015 with routine antiviral prophylaxis. 
Surveillance MRI in December 2015 demonstrated a new lesion in the anterior 
medulla but no clinical relapses were reported (Fig 1B). 
 
In January 2016, she presented to urgent care with right-sided spasms and was 
treated with gabapentin.  Three weeks later she contacted the MS service, 
describing a 10-day history of events consistent with partial seizures comprising 
dysgeusia, speech arrest and left head version. Levetiracetam was started and 
she was admitted for investigation; MRI brain showed multiple foci of poorly 
defined high T2 signal involving the left insular and perisylvian cortex, bilateral 
temporal poles and the left inferior parietal lobe. The appearances were 
considered highly suggestive of progressive multifocal leukoencephalopathy 
(PML).  
 
Three MRI scans, including contrast, were performed over the next two weeks, 
showing evolving abnormalities of the left temporal and parietal lesions (Fig1C-
D). Routine blood tests did not show any evidence of a systemic inflammatory 
response. Three CSF samples were sent for JC virus PCR to laboratories in the UK 
and Copenhagen; each was negative. CSF protein, glucose and cell counts were 
normal. CSF PCR was negative for HSV 1&2, mumps, parechovirus, enterovirus, 
VZV, HHV6 and TB.   CSF flow cytometry showed small numbers of reactive 
lymphocytes with a CD4:CD8 ratio of 1:1. Flow cytometry of blood showed 
reduced CD4+ and CD8+ T-cell numbers as follows: CD4+ 203 cells/ul (450-
1700); CD8+ 121 cells/ul (250-1100). The ratio was 1.69, within the normal 
range, as were B-lymphocyte and natural killer cell numbers.  Serum was 
negative for antibodies to NMDA receptor, VGKC complex, Ma1, CV2/CRMP5, 
amphiphysin, fix1, zic4, TR, Hu, Yi, Ro. Serology for Hepatitis B/C, HIV, 
toxoplasma, Cryptococcus and aspergillus was negative. ANA, ANCA and thyroid 
antibodies were negative. 
 
The patient declined with progressive disinhibition, euphoria and dysphasia, and 
required escalating doses of antiepileptics. A brain biopsy was performed, which 
showed demyelination within the white matter and cortical gliosis, astrocytosis 
and microvacuolation associated with neuronal loss. Within the cortex and 
leptomeninges a predominantly perivascular inflammatory cell infiltrate was 
observed, comprising lymphocytes, macrophages, eosinophils and plasma cells 
(Fig 2). In places this extended into the vessel wall, without evidence of necrosis 
or thrombosis. There was no evidence of bacteria, fungi, CMV, toxoplasma, HSV, 
VZV, measles or polyoma virus. The appearances were considered suggestive of a 
non-necrotising vasculitis; the presence of eosinophils raised the possibility of 
an allergic vasculitis, or vasculitis in the context of more widespread connective 
tissue disease. However, there was no evidence of systemic involvement and the 
patient had not been on regular medication at the time of onset. 
 
While awaiting histopathology she was treated with five-days’ plasma exchange 
and prednisolone was started (60mg daily). In light of the histological analysis 
she was given a 1g bolus of cyclophosphamide, and two weeks later started on 
oral cyclophosphamide, 2.5mg/kg/day, in addition to oral steroid maintenance. 
Lymphopaenia necessitated GCSF and a short break from cyclophosphamide, but 
she was discharged for rehabilitation 6 weeks after presentation, with 
expressive and receptive dysphasia, right sided weakness and left hemianopia. 
Five months after starting cyclophosphamide she undertook a graded return to 





Alemtuzumab is a monoclonal antibody directed against the CD52 antigen 
expressed on B-cells and T-cells of the adaptive immune system; administration 
causes long-lasting depletion of these cells via antibody-dependent and 
complement-dependent mechanisms. The lymphocyte niche is gradually 
repopulated via haematopoietic precursors, with CD8+ and CD4+ T-cell 
populations taking up to 60 months to reach previous numbers (1, 2). As seen in 
this case, the B-cell population is quicker to recover.  
 
In trials, Alemtuzumab reduced the annualized relapse rate by up to 69% 
compared with interferon-β, as well as reducing accumulation of disability (3). 
The reduction in immune cells does not appear to result in a greater 
susceptibility to significant infections, but mild and moderate infections are 
reported with greater frequency. The major adverse effect is emergence of 
secondary autoimmunity (4), which may be associated with excess repopulation 
of B-cells (5). Most common is autoimmune thyroid disease, but other 
recognized complications include immune thrombocytopaenia, and renal disease 
including anti-glomerular basement membrane disease and membranous 
glomerulonephritis. These complications usually respond well to 
immunotherapies including corticosteroids, plasma exchange and 
cyclophosphamide (4).  
 The first case of alemtuzumab-related PML in the context of multiple 
sclerosis treatment has recently been reported(6). The patient made a good 
recovery following treatment with steroids. Hitherto, PML had reportedly only 
occurred following alemtuzumab in other settings. A lung transplant recipient, 
previously treated with multiple immunosuppressants, developed PML thirteen 
months after a single 30mg dose (7), and a patient with chronic lymphocytic 
leukaemia developed PML while undergoing a 12-week course of high dose 
alemtuzumab (8). The patient died in both cases. 
A recent report describes two cases of inflammatory CNS disease 
occurring 6 months following alemtuzumab for MS, with ring-enhancing lesions 
on MRI. A prompt response to Rituximab was observed, leading the authors to 
propose that the pathology was due to the emergence of B-cell driven 
autoimmunity (9). Histology was not obtained in either of these patients, and the 
MRI appearances are markedly different to our case. There are two recent case 
reports of vasculitis in the context of alemtuzumab treatment for MS, the first a 
case of leukocytoclastic vasculitis that responded promptly to steroids (10), and 
the second a case of systemic MPO-ANCA positive polyangiitis that was also 
effectively treated with steroids alone (11). CNS vasculitis has been reported as a 
consequence of Daclizumab monotherapy in MS (12), but not other DMTs, 
suggesting that this is a treatment induced condition rather than a general 
propensity of MS patients to other autoimmune disease.  
To our knowledge this is the first case of eosinophilic CNS vasculitis in the 
context of alemtuzumab. There was no evidence of systemic connective tissue 
disease, and the improvement with cyclophosphamide after 2 months’ 
progression lends credence to the histological diagnosis. Angiography may have 
helped in this case; however, initially vasculitis was not high on the list of 
differential diagnoses, and angiography was felt to be unnecessary once the 
histological diagnosis was made. 
 Eosinophilic vasculitis is most commonly recognized in the context of 
systemic eosinophilic granulomatosis with polyangiitis (EGPA). In our case, 
granulomas were not seen, which is unusual but not unprecedented (13).  The 
role of granulocytes and the mechanism of autoimmunity remain unclear; post-
alemtuzumab autoimmunity appears to be mainly B-cell dependent, whereas the 
inflammatory infiltrate in this patient was dominated by T-cells, as in ANCA-
associated vasculitis (14). Furthermore, B-cell ‘hyper-repopulation’ was not seen 
in our case, where flow cytometry revealed normal numbers of peripheral B-
cells and a preserved CD4+/CD8+ T-cell ratio. The rapid response to 
immunotherapy and good outcome should prompt neurologists to consider the 
possibility of CNS vasculitis in this setting. 
 
Conflict of interest 
The Authors declare that there are no conflicts of interest. 
 
Acknowledgements 
We acknowledge and provide thanks to the patient and her family. We also 
acknowledge the contributions of Professor Jeremy Hobart  and Dr Omar Al-
Masri.  
Consent 
Patient consent was obtained.  
 
References 
1. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action 
of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009; 
128;2:260-70. 
2. Jones JL, Coles AJ. Mode of action and clinical studies with alemtuzumab. 
Exp Neurol 2014; 262 Pt A:37-43. 
3. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than 
interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 
2012; 78;14:1069-78. 
4. Brown JW, Coles AJ. Alemtuzumab: evidence for its potential in relapsing-
remitting multiple sclerosis. Drug Des Devel Ther 2013; 7:131-8. 
5. Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Interpreting Lymphocyte 
Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA 
Neurol 2017; 74;8:961-9. 
6. Gerevini S, Capra R, Bertoli D, et al. Immune profiling of a patient with 
alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler 
2019; 25;8:1196-201. 
7. Waggoner J, Martinu T, Palmer SM. Progressive multifocal 
leukoencephalopathy following heightened immunosuppression after lung 
transplant. J Heart Lung Transplant 2009; 28;4:395-8. 
8. Isidoro L, Pires P, Rito L, et al. Progressive multifocal 
leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated 
with alemtuzumab. BMJ Case Rep 2014; 2014. 
9. Haghikia A, Dendrou CA, Schneider R, et al. Severe B-cell-mediated CNS 
disease secondary to alemtuzumab therapy. Lancet Neurol 2017; 16;2:104-6. 
10. Garten LE, K; Lezcano, C; Spiro, J; Siuta, J; Belcher, S. Case report: 
Leukocytoclastic vasculitis in an MS patient following alemtuzumab treatment. 
Neurology 2017; 88 (16 Supplement):P5.403;. 
11. Sauer EM, Schliep S, Manger B, et al. Microscopic polyangiitis after 
alemtuzumab treatment in relapsing-remitting MS. Neurol Neuroimmunol 
Neuroinflamm 2018; 5;5:e488. 
12. Ohayon J, Oh U, Richert N, et al. CNS vasculitis in a patient with MS on 
daclizumab monotherapy. Neurology 2013; 80;5:453-7. 
13. Sommerville RB, Noble JM, Vonsattel JP, et al. Eosinophilic vasculitis in an 
isolated central nervous system distribution. BMJ Case Rep 2009; 2009. 
14. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel 
vasculitis. Nat Rev Rheumatol 2013; 9;12:731-40. 
 
 Figure 1. MRI brain imaging. A. Axial T2 prior to alemtuzumab B. Sagittal FLAIR: 
multifocal T2 hyperintense lesions affecting cortex and underlying white matter. 
C. Axial T2: new left temporal lobe lesion. D. Post-contrast scan showing 
enhancement of left temporal lesion. 
 
 
Figure 2. Brain Biopsy. Small cortical blood vessel showing prominent 
perivascular and transmural inflammation including scattered eosinophils. 
Haematoxylin/Eosin stain. Magnification x 200. 
 
 
